This study is looking at how well children and young adults (ages 1 to 23) with B-cell Acute Lymphoblastic Leukemia/Lymphoma (B-ALL/Ly) keep their protection from routine childhood vaccinations after being treated with blinatumomab. Blinatumomab is an immunotherapy that targets CD19 on cancer cells. Researchers want to see if your body still has enough protective antibodies from your childhood vaccines at least six months after finishing blinatumomab. They also want to know if getting revaccinated helps restore this protection if your antibody levels are low. The study will compare results from those who received immunotherapy to those who didn't, to understand if immunotherapy affects vaccine protection differently than other chemotherapy drugs. This is an observational study, meaning you won't receive new treatments as part of the study, but your health information will be collected. The study aims to enroll 300 participants, but its current status is unclear.

Study design

This is an observational study, meaning researchers will collect information without giving new treatments. It plans to include 300 participants.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

Researchers will measure protective antibody levels at least six months after you complete blinatumomab therapy.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.